[{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CART-TnMUC1-01","moa":"T cell","graph1":"Oncology","graph2":"Phase I","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kite Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Fosun Kite Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Fosun Kite Biotechnology","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fosun Kite Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Fosun Kite Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"GMCSF","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Xiangxue Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Xiangxue Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xiangxue Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Xiangxue Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Iovance Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"TC-210","moa":"Mesothelin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TCR2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD8+ T Cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"GM-CSF","graph1":"Oncology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Epitopoietic Research Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoietic Research Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AVA-001","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Avalon GloboCare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"AVA-001","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Avalon GloboCare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avalon GloboCare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Avalon GloboCare \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement C5","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Epitopoietic Research Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoietic Research Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Brexucabtagene autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suspension for Intravenous Infusion","sponsorNew":"Dana-Farber Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dana-Farber Cancer Institute \/ Not Applicable"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"TC-210","moa":"Mesothelin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TCR2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Public Offering","leadProduct":"Eflapegrastim","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Spectrum Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Spectrum Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"NTN Buzztime","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Merger","leadProduct":"Cyclophosphamide","moa":"IL-2","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ NTN Buzztime","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn ImmunoTherapeutics \/ NTN Buzztime"},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Center for International Blood and Marrow Transplant Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase IV","graph3":"Center for International Blood and Marrow Transplant Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Center for International Blood and Marrow Transplant Research \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Center for International Blood and Marrow Transplant Research \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Genetic Disease","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CAR-NKT Cell","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kuur Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM13-NK cells","moa":"CD30","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kuur Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Mustang Bio \/ Not Applicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Not Applicable"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals, Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion Pharmaceuticals, Inc."},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Fortress Biotech \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"GCSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen \/ Not Applicable"},{"orgOrder":0,"company":"Celyad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"CYAD-211","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Celyad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Celyad \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Celyad \/ Not Applicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"MB-106","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Not Applicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Janssen Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Janssen Pharmaceutical"},{"orgOrder":0,"company":"ElevateBio","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"TC-210","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ElevateBio \/ TCR\u00b2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"ElevateBio \/ TCR\u00b2 Therapeutics"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AFM13-NK cells","moa":"CD30","graph1":"Oncology","graph2":"Phase I","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Not Applicable"},{"orgOrder":0,"company":"Genexine","sponsor":"NeoImmuneTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"IL-7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Genexine \/ NeoImmuneTech","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ NeoImmuneTech"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Survivin","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Daratumumab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Dana-Farber Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Dana-Farber Cancer Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Dana-Farber Cancer Institute \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Dana-Farber Cancer Institute \/ Not Applicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Not Applicable"},{"orgOrder":0,"company":"InnoCare Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Orelabrutinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"InnoCare Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"InnoCare Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"InnoCare Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kuur Therapeutics \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Targovax","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Theradex"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Farallon Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series C Financing","leadProduct":"CB-010","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0.12,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Farallon Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Farallon Capital Management"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Avacopan","moa":"C5a receptor","graph1":"Immunology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amgen Inc \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Servier","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Servier","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Intravenous infusion","sponsorNew":"Servier \/ Precision BioSciences","highestDevelopmentStatusID":"7","companyTruncated":"Servier \/ Precision BioSciences"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Genetic Disease","graph2":"Approved","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Humanigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"GCSF","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Humanigen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Humanigen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanigen \/ Not Applicable"},{"orgOrder":0,"company":"Kuur Therapeutics","sponsor":"Athenex","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kuur Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Intravenous infusion","sponsorNew":"Kuur Therapeutics \/ Athenex","highestDevelopmentStatusID":"6","companyTruncated":"Kuur Therapeutics \/ Athenex"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Belimumab","moa":"","graph1":"Nephrology","graph2":"Approved","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Therapeutic Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Therapeutic Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Therapeutic Solutions \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Therapeutic Solutions \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Kingswood Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ Kingswood Capital Markets","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Kingswood Capital Markets"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Bortezomib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kite Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Centocor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Daratumumab","moa":"CD38","graph1":"Genetic Disease","graph2":"Approved","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Centocor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Centocor \/ Not Applicable"},{"orgOrder":0,"company":"Gliknik","sponsor":"First In Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Series C Financing","leadProduct":"Biropepimut-S","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Gliknik","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Injection","sponsorNew":"Gliknik \/ First In Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Gliknik \/ First In Ventures"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"B-Cell maturation antigen","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"FT516","moa":"hnCD16 Fc receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.5,"dosageForm":"Sterile Solution","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Acepodia","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"ACE1702","moa":"HER1\/HER2","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Acepodia \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Not Applicable"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Triumvira Immunologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Not Applicable"},{"orgOrder":0,"company":"TCR2 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TCR2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TCR2 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TCR2 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.5,"dosageForm":"Sterile Solution","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Nationwide Children\u2019s Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Nationwide Children\u2019s Hospital"},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"CAR-NKT Cell","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Qiagen","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Enzastaurin","moa":"PKC beta","graph1":"Oncology","graph2":"Phase III","graph3":"Qiagen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Qiagen \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Qiagen \/ Denovo Biopharma"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"FT516","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Arbor Biotechnologies, Inc","sponsor":"TCR2 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Arbor Biotechnologies, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arbor Biotechnologies, Inc \/ TCR2 Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Arbor Biotechnologies, Inc \/ TCR2 Therapeutics"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD22","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Not Applicable"},{"orgOrder":0,"company":"Intima Bioscience","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"CISH","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intima Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intima Bioscience \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Intima Bioscience \/ MaxCyte"},{"orgOrder":0,"company":"Gracell Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Anti-CD19 UCAR-T","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Gracell Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gracell Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gracell Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Genmab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD3","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genmab \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"T cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Enochian BioSciences","sponsor":"Caring Cross","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Cyclophosphamide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Enochian BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Enochian BioSciences \/ Caring Cross","highestDevelopmentStatusID":"7","companyTruncated":"Enochian BioSciences \/ Caring Cross"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ExCellThera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ExCellThera \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"cyclophosphamide","moa":"T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"Mabxience","sponsor":"Fresenius Kabi AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Rituximab","moa":"CD20","graph1":"Oncology","graph2":"Approved","graph3":"Mabxience","amount2":0.55000000000000004,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Fresenius","highestDevelopmentStatusID":"12","companyTruncated":"Mabxience \/ Fresenius"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"WT1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"ATEM Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Triumvira Immunologics \/ ATEM Capital","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ ATEM Capital"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AFM13","moa":"CD30","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Affimed \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Intravenous","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"Intravenous","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.23000000000000001,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Cowen","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Cowen"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CB-010","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic CD19 CAR-NKT Cells","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"VITRAC Therapeutics","sponsor":"University of Minnesota Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Aurora kinase A","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"VITRAC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"VITRAC Therapeutics \/ University of Minnesota Medical School","highestDevelopmentStatusID":"7","companyTruncated":"VITRAC Therapeutics \/ University of Minnesota Medical School"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Maveropepimut-S","moa":"T cell","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Athenex \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ Not Applicable"},{"orgOrder":0,"company":"Lyell Immunopharma","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"NY-ESO-1","graph1":"Oncology","graph2":"Phase I","graph3":"Lyell Immunopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lyell Immunopharma \/ GSK","highestDevelopmentStatusID":"6","companyTruncated":"Lyell Immunopharma \/ GSK"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Myeloid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Myeloid Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Myeloid Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"AUTO4","moa":"TRBC1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Not Applicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CB-010","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Allogeneic Ex-vivo Generated NK cells","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Glycostem Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Termination","leadProduct":"ATA2271","moa":"Mesothelin protein","graph1":"Oncology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0.67000000000000004,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Atara Biotherapeutics \/ Bayer","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Bayer"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"Folate receptor alpha","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Instil Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"CD20","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Brexucabtagene Autoleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adaptive Biotechnologies \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Biotechnologies \/ Not Applicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CB-010","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"MB-106","moa":"CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mustang Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Epitopoietic Research Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Epitopoietic Research Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Epitopoietic Research Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Epitopoietic Research Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Genexine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"IL-7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Genexine \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Genexine \/ Not Applicable"},{"orgOrder":0,"company":"Brooklyn ImmunoTherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Brooklyn ImmunoTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Brooklyn ImmunoTherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Brooklyn ImmunoTherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Glycostem Therapeutics","sponsor":"Medac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Glycostem Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Glycostem Therapeutics \/ Medac GmbH","highestDevelopmentStatusID":"7","companyTruncated":"Glycostem Therapeutics \/ Medac GmbH"},{"orgOrder":0,"company":"Aileron Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ALRN-6924","moa":"MDM2\/MDMX","graph1":"Oncology","graph2":"Phase I","graph3":"Aileron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Aileron Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Aileron Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Athenex","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Athenex","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Athenex \/ SVB Securities","highestDevelopmentStatusID":"6","companyTruncated":"Athenex \/ SVB Securities"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Avacopan","moa":"Complement 5a receptor","graph1":"Immunology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CSL Vifor \/ ChemoCentryx","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ ChemoCentryx"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"LSD1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"TAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Celularity","sponsor":"YA II PN","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Agreement","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Celularity","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.14999999999999999,"dosageForm":"Infusion","sponsorNew":"Celularity \/ YA II PN","highestDevelopmentStatusID":"7","companyTruncated":"Celularity \/ YA II PN"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kite Pharma \/ Gilead Sciences","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharma \/ Gilead Sciences"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD117","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jasper Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"CD16","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"TIL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Iovance Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Caring Cross","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"duoCAR-T Cell","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Caring Cross","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Caring Cross \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"Caring Cross \/ University of California"},{"orgOrder":0,"company":"Kite Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Kite Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kite Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kite Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Triumvira Immunologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"TAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Triumvira Immunologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Triumvira Immunologics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Triumvira Immunologics \/ Not Applicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Birtamimab","moa":"Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Not Applicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CAN-3110","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"G1 Therapeutics, Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Trilaciclib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"G1 Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"G1 Therapeutics, Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"G1 Therapeutics, Inc \/ Not Applicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Birtamimab","moa":"","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prothena \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Jefferies"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"ADI-001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"FT819","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cellectis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cellectis \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellectis \/ Not Applicable"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CB-010","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"IMV","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2022","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"CASI Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"CASI Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CASI Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CASI Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Janssen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Termination","leadProduct":"Allogenic CAR NK Cell","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":3.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":3.1000000000000001,"dosageForm":"","sponsorNew":"Fate Therapeutics \/ Janssen","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Janssen"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Instil Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Instil Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Instil Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Instil Bio \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPharm \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"IMV","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"IMV","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"IMV \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"IMV \/ Not Applicable"},{"orgOrder":0,"company":"Precigen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Precigen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Precigen \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Precigen \/ Not Applicable"},{"orgOrder":0,"company":"Alaunos Therapeutics","sponsor":"Precigen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Autologous CAR-T Cell-based Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Alaunos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alaunos Therapeutics \/ Precigen","highestDevelopmentStatusID":"6","companyTruncated":"Alaunos Therapeutics \/ Precigen"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Adaptive Biotechnologies \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Adaptive Biotechnologies \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ Spartan Capital Securities","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Spartan Capital Securities"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Prevail Partners"},{"orgOrder":0,"company":"Immunai","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Immunai","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Immunai \/ Baylor College of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Immunai \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Myeloid Therapeutics","sponsor":"Hatteras Investment Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Myeloid Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Infusion","sponsorNew":"Myeloid Therapeutics \/ Hatteras Investment Partners","highestDevelopmentStatusID":"7","companyTruncated":"Myeloid Therapeutics \/ Hatteras Investment Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Prevail Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BriaCell Therapeutics \/ Prevail Partners","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Prevail Partners"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWEDEN","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Acepodia","sponsor":"Digital Mobile Venture","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TAIWAN","productType":"Cell and Gene therapy","year":"2023","type":"Series D Financing","leadProduct":"Allogenic Gamma Delta T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Acepodia","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Acepodia \/ Digital Mobile Venture","highestDevelopmentStatusID":"6","companyTruncated":"Acepodia \/ Digital Mobile Venture"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Texcell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Valo Therapeutics \/ Texcell","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Texcell"},{"orgOrder":0,"company":"Vyriad","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vyriad","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vyriad \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Vyriad \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Georgetown University","sponsor":"Cantex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Azeliragon","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Georgetown University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgetown University \/ Cantex Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Georgetown University \/ Cantex Pharmaceuticals"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"ADI-001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Iovance Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"LN-145","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Iovance Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Iovance Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Iovance Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Invectys","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invectys \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ M.D. Anderson Cancer Center"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"CB-010","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Caribou Biosciences \/ BofA Securities","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ BofA Securities"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"CB-010","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Precision BioSciences \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Invectys","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Invectys","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Invectys \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Invectys \/ Not Applicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0.66000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.66000000000000003,"dosageForm":"Infusion","sponsorNew":"Precision BioSciences \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Imugene"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Axicabtagene Ciloleucel","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gilead Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Gilead Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"BEAM-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beam Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"GC Cell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AB-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"GC Cell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"GC Cell \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"GC Cell \/ Not Applicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ MaxCyte"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"ADI-001","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Jefferies"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CABA-201","moa":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Kyverna Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Kyverna Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.37,"dosageForm":"Infusion","sponsorNew":"Kyverna Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Kyverna Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"CAN-3110","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Immunovaccine Technologies","sponsor":"Biovaxys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Acquisition","leadProduct":"Maveropepimut-S","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Immunovaccine Technologies","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Immunovaccine Technologies \/ BioVaxys","highestDevelopmentStatusID":"8","companyTruncated":"Immunovaccine Technologies \/ BioVaxys"},{"orgOrder":0,"company":"Salarius Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Seclidemstat","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Salarius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Salarius Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Salarius Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"AB-101","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Artiva Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Artiva Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Artiva Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Batavia Bioscience","sponsor":"Candel Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"CAN-3110","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Batavia Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Batavia Bioscience \/ Candel Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Batavia Bioscience \/ Candel Therapeutics"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CB-012","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Caribou Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Caribou Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Caribou Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Acimtamig","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Affimed \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"Affimed \/ M.D. Anderson Cancer Center"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Replay Bio","sponsor":"Syena","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Replay Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Replay Bio \/ Syena","highestDevelopmentStatusID":"7","companyTruncated":"Replay Bio \/ Syena"},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Not Applicable"},{"orgOrder":0,"company":"Valo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Valo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Valo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Valo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Obsidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Obsidian Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Obsidian Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kincell Bio","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Kincell Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kincell Bio \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Kincell Bio \/ Imugene"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"ALLO-316","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TC BioPharm \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"TC BioPharm \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"Fate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Fate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Fate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ADI-001","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Cabaletta Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CABA-201","moa":"","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Cabaletta Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Cabaletta Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cabaletta Bio \/ Not Applicable"},{"orgOrder":0,"company":"ExCellThera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"ExCellThera \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"ExCellThera \/ Not Applicable"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ CPRIT","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ CPRIT"},{"orgOrder":0,"company":"KSQ Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"KSQ Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"KSQ Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"KSQ Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"CAN-3110","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Candel Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Candel Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"AB-101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Artiva Biotherapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"","sponsorNew":"Artiva Biotherapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Artiva Biotherapeutics \/ Jefferies"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ADI-270","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Imugene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Azercabtagene Zapreleucel","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Imugene \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Allogeneic Gamma Delta T Cell Therapy","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"TC BioPharm \/ Undisclosed"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ADI-001","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"AvenCell Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"AVC-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"AvenCell Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"","sponsorNew":"AvenCell Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"AvenCell Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"ScaleReady","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"Cyclophosphamide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ ScaleReady","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ ScaleReady"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CEL-SCI \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Autolus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Autolus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Autolus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Autolus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Nkarta Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Nephrology","graph2":"Phase I","graph3":"Nkarta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"","sponsorNew":"Nkarta Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nkarta Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adaptimmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adaptimmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adaptimmune Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adaptimmune Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Allogene Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ALLO-316","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Allogene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Allogene Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Allogene Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ADI-001","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sana Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Immunology","graph2":"Phase I","graph3":"Sana Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Sana Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sana Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Blinatumomab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"ADI-270","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adicet Bio \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Adicet Bio \/ Not Applicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"ThinkEquity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"CEL-SCI \/ ThinkEquity","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ ThinkEquity"},{"orgOrder":0,"company":"Indapta Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Indapta Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Indapta Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Indapta Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"BriaCell Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"BriaCell Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Affimed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"AB-101","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Affimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Affimed \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Affimed \/ Not Applicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Hansa Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hansa Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Eflapegrastim","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Assertio Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Assertio Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ibrutinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Vittoria Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Vittoria Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Vittoria Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Vittoria Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Not Applicable"},{"orgOrder":0,"company":"JW Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||CD19","graph1":"Oncology","graph2":"Phase II","graph3":"JW Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"JW Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"JW Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BriaCell Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Bria-OTS","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"BriaCell Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"BriaCell Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BriaCell Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adicet Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ADI-001","moa":"||CD20","graph1":"Nephrology","graph2":"Phase I","graph3":"Adicet Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adicet Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Adicet Bio \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||ROR1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius SE & Co. KGaA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Approved FDF","graph3":"Fresenius SE & Co. KGaA","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Fresenius SE & Co. KGaA \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius SE & Co. KGaA \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Brentuximab Vedotin","moa":"||CD30","graph1":"Oncology","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Ingenus Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Licensing Agreement","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Ingenus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ingenus Pharmaceuticals \/ Dr. Reddy\\'s Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Ingenus Pharmaceuticals \/ Dr. Reddy\\'s Laboratories"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Approved FDF","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ZYUS Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ZYUS Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Nevakar Injectables","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Approved FDF","graph3":"Nevakar Injectables","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nevakar Injectables \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nevakar Injectables \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Chipscreen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Chidamide","moa":"||HDAC","graph1":"Oncology","graph2":"Approved FDF","graph3":"Shenzhen Chipscreen Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Shenzhen Chipscreen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Shenzhen Chipscreen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"JAPAN","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Polatuzumab Vedotin","moa":"||CD79b","graph1":"Oncology","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"NMDP","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"NMDP","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NMDP \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMDP \/ Inapplicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||ROR1","graph1":"Oncology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Inapplicable"},{"orgOrder":0,"company":"Aim ImmunoTech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"||TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Aim ImmunoTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aim ImmunoTech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aim ImmunoTech \/ Inapplicable"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"TC BioPharm \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TC BioPharm \/ Inapplicable"},{"orgOrder":0,"company":"CEL-SCI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"CEL-SCI","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Peritumoral Injection","sponsorNew":"CEL-SCI \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CEL-SCI \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for (-)-Cyclophosphamide
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
